Initial studies in humans suggest that NLRP3 inflammasome activation in obesity could be important in development and treatment of insulin-resistance and diabetes [Figure 2; (Larsen et al., 2007; Vandanmagsar et al., 2011; Goossens et al., 2012)]. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.